AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02233608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Pelvic Floor Muscle Exercise (APFX)
Study NCT01207804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ValenTx Endo Bypass System
Description: Patient is implanted with device and followed for 12 weeks
Study NCT01347073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (\~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
Study NCT01728649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild Hypothermia
Description: Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
Study NCT03944460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study NCT01467128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured expert pharmacist review
Description: The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
Study NCT00596349 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
Study NCT00596349 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
Study NCT02330601 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic papillary large balloon dilation
Description: For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
Study NCT06092840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Transform Burn
Description: Study product Transform Burn contains dihydrocapsiate, red pepper (Capsicum annuum) fruit extract, citrus (Citrus spp) peel extract, coleus (Coleus forskholi) root extract, and african mango (Irvingia gabonensis) seed extract.
Study NCT01467128 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No Intervention
Description: Normal hospital pharmaceutical care
Study NCT02530190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent pneumatic compression
Description: 20 minutes of intermittent pneumatic compression to lower extremities
Study NCT02530190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: 20 minutes of massage to lower extremities
Study NCT03808844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
Study NCT03808844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
Study NCT00822640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
Study NCT00822640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
Study NCT04801355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full-thickness laparo-endoscopic colon adenomas excision
Description: Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
Study NCT04801355 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic colon resection
Description: Standard laparoscopic colon resection
Study NCT01599949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
Study NCT02017067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hydraulic resistance circuit training
Description: 12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
Study NCT03887325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxipost
Description: To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study NCT03887325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
Study NCT03621124 — intervention group
Intervention type: PROCEDURE
Intervention: Resting Energy Expenditure
Description: During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
Study NCT01189149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IV fluids
Description: Infants will be allocated to IV fluids
Study NCT01189149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naso/oro gastric tube feedings
Description: Infants will be allocated to naso/oro gastric tube feedings
Study NCT03621124 — intervention group
Intervention type: OTHER
Intervention: Thermal Comfort Questionnaire
Description: Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
Study NCT05592444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low iodine Spectral Detector CT Pulmonary Angiography
Description: Low iodine Spectral Detector CT Pulmonary Angiography
Study NCT00483054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: efavirenz 600 mg/day + stavudine + lamivudine
Study NCT03490760 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
Study NCT00620087 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
Study NCT03402854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation
Description: Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
Study NCT03402854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bimanual training
Description: Participants will engage in movements that use both hands, by playing with toys and games.
Study NCT02766946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
Study NCT02766946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
Study NCT02766946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
Study NCT02766946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
Study NCT02766946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromyopathy score
Description: A neuromyopathy score will be assessed on the extubation day
Study NCT02766946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromyopathy score
Description: A neuromyopathy score will be assessed on the extubation day
Study NCT00676728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-26481585
Description: In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
Study NCT00483054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nevirapine
Description: nevirapine 400 mg/day + stavudine +lamivudine
Study NCT02120781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azficel-T (autologous fibroblasts)
Description: Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril.
Study NCT02120781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
Study NCT02766946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory performances
Description: An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
Study NCT02766946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory performances
Description: An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
Study NCT02588313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mango fruit powder
Description: Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
Study NCT02588313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mango fruit powder
Description: Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
Study NCT03199014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deploying the Drug-eluting Stents with a prolonged time
Description: the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
Study NCT03199014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deploying the Drug-eluting Stents with a conventional time
Description: the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
Study NCT01925014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic CT with low-dose radiation
Description: Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
Study NCT00620087 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Mammography
Description: A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
Study NCT01832779 — intervention group
Intervention type: OTHER
Intervention: Achalasia subjects
Description: Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
Study NCT04635293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative infusion of levosimendan
Description: the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
Study NCT01925014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic CT with standard-dose radiation
Description: Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
Study NCT00706264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring (Arabin Pessary)
Description: Placement of a silicon pessary in the vagina, around the cervix.
Study NCT00372489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
Study NCT05148429 — intervention group
Intervention type: OTHER
Intervention: Ultrasound exam
Description: Ultrasound exam
Study NCT05148429 — intervention group
Intervention type: OTHER
Intervention: Fetal MRI
Description: Fetal MRI
Study NCT05148429 — intervention group
Intervention type: OTHER
Intervention: Postnatal abdominal ultrasound
Description: Postnatal abdominal ultrasound
Study NCT05148429 — intervention group
Intervention type: OTHER
Intervention: Pediatric Follow up
Description: Pediatric Follow up
Study NCT01511640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 2x daily for duration of study
Study NCT01511640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2x daily for duration of study
Study NCT01251991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psyllium husks
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study NCT04635293 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no preoperative infusion of levosimendan
Description: the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
Study NCT00699283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
Study NCT02757898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin-Labeled Red Blood Cells (RBCs)
Description: 500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs.
Study NCT04650191 — intervention group
Intervention type: OTHER
Intervention: Identification of genetic variants
Description: DNA will be extracted from whole blood from study subjects
Study NCT01251991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium husks
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study NCT01251991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Description: Oral suspension, oral use, 30 grams once per day
Study NCT01251991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolated soy protein
Description: Oral suspension, oral use, 30 grams once per day
Study NCT00699283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
Study NCT04077918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein diet
Description: 100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
Study NCT02685566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFDM Plus DBT
Description: FujiFilm Aspire Cristalle System
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 2mg/dose by nebulizer, four doses over 3 hours
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol
Description: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Study NCT01251991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolated whey protein
Description: Oral suspension, oral use, 30 grams once per day
Study NCT00588406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: 2.5 mg, one dose
Study NCT02685566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFDM
Description: FujiFilm Aspire Cristalle System
Study NCT01661751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Vaccine
Description: 600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime